Two commercialized assays are FDA approved for CRC screening: Epi ProColon 2.0, analyzing SEPT9 DNA methylation in blood; Cologuard test®, stool-based that analyses NDRG4 and BMP3 methylation and KRAS mutation [20, 21]. Here, KRAS is linked to colorectal carcinoma.